ArticleJournal of virology2005
Compartmentalized human immunodeficiency virus type 1 present in cerebrospinal fluid is produced by short-lived cells.
Article in Journal of virology, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 61 citations in OpenAlex.
- Raltegravir treatment intensification does not alter cerebrospinal fluid HIV-1 infection or immunoactivation in subjects on suppressive therapy.The Journal of infectious diseases · 2011Trial
- Trial
- HIV-1 is Transported into the Central Nervous System by Trafficking Infected Cells.Pathogens & immunity · 2022Article
- T cell derived HIV-1 is present in the CSF in the face of suppressive antiretroviral therapy.PLoS pathogens · 2021Article
- HIV/neuroAIDS biomarkers.Progress in neurobiology · 2017Review
- Dynamic of CSF and serum biomarkers in HIV-1 subtype C encephalitis with CNS genetic compartmentalization-case study.Journal of neurovirology · 2017Article
- Envelope gene evolution and HIV-1 neuropathogenesis.Journal of neuroinfectious diseases · 2015Article
- Compartmentalized intrathecal immunoglobulin synthesis during HIV infection - a model of chronic CNS inflammation?Journal of neuroimmunology · 2015Review
- Genetic shift of env V3 loop viral sequences in patients with HIV-associated neurocognitive disorder during antiretroviral therapy.Journal of neurovirology · 2013Article
- The cerebrospinal fluid proteome in HIV infection: change associated with disease severity.Clinical proteomics · 2012Article
- The HIV-1 env protein: a coat of many colors.Current HIV/AIDS reports · 2012Review
- HIV variability in the liver and evidence of possible compartmentalization.AIDS research and human retroviruses · 2011Article
- HIV-1 replication in the central nervous system occurs in two distinct cell types.PLoS pathogens · 2011Article
- The neuropathogenesis of feline immunodeficiency virus infection: barriers to overcome.Veterinary journal (London, England : 1997) · 2011Review
- Minocycline fails to modulate cerebrospinal fluid HIV infection or immune activation in chronic untreated HIV-1 infection: results of a pilot study.AIDS research and therapy · 2011Article
- Compartmentalization and clonal amplification of HIV-1 variants in the cerebrospinal fluid during primary infection.Journal of virology · 2010Article
- Should antiretroviral therapy for HIV infection be tailored for intracerebral penetration?The Netherlands journal of medicine · 2009Review
- Cross-sectional characterization of HIV-1 env compartmentalization in cerebrospinal fluid over the full disease course.AIDS (London, England) · 2009Article
- Major coexisting human immunodeficiency virus type 1 env gene subpopulations in the peripheral blood are produced by cells with similar turnover rates and show little evidence of genetic compartmentalization.Journal of virology · 2009Article
- Compartmentalized human immunodeficiency virus type 1 originates from long-lived cells in some subjects with HIV-1-associated dementia.PLoS pathogens · 2009Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 4 institutions in 3 countries.
Funding
Abstract
Human immunodeficiency virus type 1 (HIV-1) invades the central nervous system (CNS) during primary infection and persists in this compartment by unknown mechanisms over the course of infection. In this study, we examined viral population dynamics in four asymptomatic subjects commencing antiretroviral therapy to characterize cellular sources of HIV-1 in the CNS. The inability to monitor viruses directly in the brain poses a major challenge in studying HIV-1 dynamics in the CNS. Studies of HIV-1 in cerebrospinal fluid (CSF) provide a useful surrogate for the sampling of virus in the CNS, but they are complicated by the fact that infected cells in local CNS tissues and in the periphery contribute to the population pool of HIV-1 in CSF. We utilized heteroduplex tracking assays to differentiate CSF HIV-1 variants that were shared with peripheral blood plasma from those that were compartmentalized in CSF and therefore presumably derived from local CNS tissues. We then tracked the relative decline of individual viral variants during the initial days of antiretroviral therapy. We found that HIV-1 variants compartmentalized in CSF declined rapidly during therapy, with maximum half-lives of approximately 1 to 3 days. These kinetics emulate the decline in HIV-1 produced from short-lived CD4+ T cells in the periphery, suggesting that a similarly short-lived, HIV-infected cell population exists within the CNS. We propose that short-lived CD4+ T cells trafficking between the CNS and the periphery play an important role in amplifying and maintaining HIV-1 populations in the CNS during the asymptomatic phase of infection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.